Core Points - The conference call is focused on the positive 9-month update from Immuneering's ongoing Phase IIa trial of atebemetinib in first-line pancreatic cancer patients [1] - Key executives from Immuneering, including the CEO and Chief Scientific Officer, are present on the call to discuss the trial results and future plans [2] Company Updates - Immuneering is currently conducting a Phase IIa trial for atebemetinib, which is aimed at treating first-line pancreatic cancer patients [1][3] - The management team is expected to provide forward-looking statements regarding the trial and the timing of additional data [3][4]